KIVEXA

This brand name is authorized in Austria, Australia, Canada, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, South Africa

Active ingredients

The drug KIVEXA contains a combination of these active pharmaceutical ingredients (APIs):

1 Abacavir UNII J220T4J9Q2 - ABACAVIR SULFATE

Abacavir is a NRTI. It is a potent selective inhibitor of HIV-1 and HIV-2. Abacavir is metabolised intracellularly to the active moiety, carbovir 5'-triphosphate (TP). In vitro studies have demonstrated that its mechanism of action in relation to HIV is inhibition of the HIV reverse transcriptase enzyme, an event which results in chain termination and interruption of the viral replication cycle. Read about Abacavir

2 Lamivudine UNII 2T8Q726O95 - LAMIVUDINE

Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription. Read about Lamivudine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
KIVEXA Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AR02	Lamivudine and abacavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10357D
Country: CA	Health Products and Food Branch	Identifier(s): 02269341
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 00462309, 00605571, 00910535, 01179691, 01718171, 01746345, 01973130, 02163893, 02163901, 04169730, 04911709, 04980030, 05495130, 06063958, 06560616, 06867674, 07745565, 10335428, 10335440, 11662649, 11722794, 12344472, 12575852, 13825400, 14227061, 14227078, 16529642
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 2931-MEE-0717
Country: EE	Ravimiamet	Identifier(s): 1198515, 1367344
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 04298002
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 101961
Country: FR	Base de données publique des médicaments	Identifier(s): 69855489
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 368072, 89918
Country: HK	Department of Health Drug Office	Identifier(s): 53855
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1029332, 1056547
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 479M2005
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 136050
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 11560
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100137983
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W65115001, W65115002
Country: SG	Health Sciences Authority	Identifier(s): 13230P
Country: ZA	Health Products Regulatory Authority	Identifier(s): A39/20.2.8/0030